secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0000950170-23-010956
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports FY2022 net loss $28.5M; cash $18.2M; clinical data positive
--------------------------------------------------------------------------

- Cash $18.2M at Dec 31, 2022, down from $37.0M a year earlier; R&D spend $14.1M (FY2022) vs $7.3M.
- Net loss $28.5M ($1.36/share) for FY2022 vs $14.7M ($1.47/share) in FY2021; Q4 loss $7.8M ($0.32/share).
- INB-100 leukemia patients maintain durable complete responses beyond 18 months, up to 2.7 years in Phase 1.
- INB-200 GBM trial: two patients progression-free at 1.5 and 1.2 years; enrolling Cohort 3; updated data mid-2023.
- FDA cleared IND for INB-400 Phase 2 trial in GBM; enrollment expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000095017023010956/0000950170-23-010956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000095017023010956/inab-20230330.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer